DVAX - חוב כולל להון Dynavax Technologies Corporation

The debt-to-equity ratio history of Dynavax Technologies (DVAX) demonstrates financial stability, where 0.52 represents the current metric. This trend is driven by partnerships to enhance drug immune responses and a reliance on hepatitis B vaccine sales, which is offset by licensing payments. Stability is supported by its leadership status in developing adjuvant platforms and investments in combating liver infections.

This indicator measures the proportion of borrowed funds relative to equity, determining the company's degree of financial autonomy. Analyzing the total liabilities-to-equity ratio allows for an assessment of the business's resilience to rising interest rates. Sharp fluctuations in the line signal increasing credit risks and potential asset volatility. The low debt load of Dynavax Technologies (DVAX) provides flexibility for development, supporting the expansion of their unique two-dose HEPLISAV-B vaccine.